Objective: To investigate the relationship between serum fibroblasts growth factor (FGF) 19 level and the development of atherosclerosis (AS) in patients with type 2 diabetes mellitus (T2DM). Methods: A total of 78 T2DM patients were selected and divided into two groups based on carotid intima-media thickness (CIMT). Among them, 40 T2DM patients were control group and 38 T2DM patients with AS were experimental group. Record the blood pressure and body mass index (BMI) of all inclusive patients. Detection of related biochemical indicators such as blood sugar, blood lipids. Serum FGF19, heme oxygenase-1 (HO-1),malondialdehyde (MDA), glutathione peroxidase (GSH-Px) levels were measured by enzyme-linked adsorption immunosorbent assay (ELISA), and superoxide peroxide dismutase (SOD) level was determined by biochemical method. The differences in outcome measures between the two sets were compared. The correlations between FGF19 level and HO-1, SOD, MDA, GSH-Px, CIMT and brachial ankle pulse wave velocity (baPWV) were analyzed by Pearson correlation analysis. Multiple linear regression analysis was performed to analyze the influencing factors of FGF19. Results: Compared with the control group, CIMT, baPWV, HO-1, MDA increased in the experimental group (P＜0.01), FGF19, SOD and GSH-Px decreased significantly compared with the control group (P＜0.01). Correlation analysis showed that the serum FGF19 level of the experimental group was negatively correlated with HO-1, MDA, CIM, baPWV(r=-0.668、-0.657、-0.901、-0.734,P＜0.01) were positively correlated with SOD and GSH-px (r=0.345、0.760,P＜0.01).Multiple linear regression analysis showed that FGF19, HO-1, SOD, MDA, GSH-PX were all the possible influencing factors of CIMT (P＜0.05). Conclusion: Serum FGF19 level in T2DM patients has a certain relationship with oxidative stress, and has important clinical significance in predicting the occurrence and progression of AS.
GAO Han
,
JIN Guoxi
,
WANG Huimin
,
PEI Xiaoyan
. Relationship analysis between serum FGF19 and oxidative stress in type 2 diabetic patients with atherosclerosis[J]. Journal of Baotou Medical College, 2023
, 39(11)
: 32
-36
.
DOI: 10.16833/j.cnki.jbmc.2023.11.006
[1] Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res ClinPract, 2020, 162: 108086.
[2] Tang MJ, Su JB, Xu TL,et al. Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients[J]. Diabetol Metab Syndr, 2019, 11: 79.
[3] Henriksson E, Andersen B. FGF19 and FGF21 for the treatment of NASH-Two sides of the same coin? differential and overlapping effects of FGF19 and FGF21 from mice to human[J]. Front Endocrinol (Lausanne), 2020, 11: 601349.
[4] Zhang J, Li H, Bai N, et al. Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner[J]. J Endocrinol Invest, 2019, 42: 1019-1027.
[5] Furukawa S, Fujita T, Shimabukuro M,et al. Increased oxidative stress in obesity and its impact on metabolic syndrome[J]. J Clin Invest, 2004, 114: 1752-1761.
[6] de M Bandeira S, da Fonseca LJ, da S Guedes G,et al. Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus[J]. Int J Mol Sci, 2013, 14: 3265-3284.
[7] Chatuphonprasert W, Lao-Ong T, Jarukamjorn K. Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide-induced type 2-diabetes in mice by berberine and glibenclamide[J]. Pharm Biol, 2013, online ahead of print.
[8] Yaribeygi H, Atkin Stephen L, Sahebkar A, et al.A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress[J]. J Cell Physiol, 2019, 234: 1300-1312.
[9] Yaribeygi H, Butler Alexandra E, Barreto George E, et al. Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients[J]. J Cell Physiol, 2019, 234: 2436-2446.
[10] Yuan T, Yang T, Chen H, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis[J]. Redox Biol, 2019, 20: 247-260.
[11] Azemi Ahmad K, Mokhtar Siti S, Hou Low J, et al. Model for type 2 diabetes exhibits changes in vascular function and structure due to vascular oxidative stress and inflammation[J]. Biotech Histochem, 2021, 96: 498-506.
[12] Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23[J]. Nat Rev Drug Discov, 2016, 15(1): 51-69.
[13] Massafra V, Pellicciari R, Gioiello A, et al. Progress and challenges of selective Farnesoid X Receptor modulation[J]. Pharmacol Ther, 2018, 191: 162-177.
[14] Byun S, Jung H, Chen J, et al. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis[J]. J Biol Chem, 2019, 294: 8732-8744.
[15] Xu M, Huang Y, Xie L, et al. Diabetes and risk of arterial stiffness: a mendelian randomization analysis[J]. Diabetes, 2016, 65: 1731-1740.
